• Home
  • Contact Us
  • Try it!
  • Blog
  • Vizit Graphs

Follow us

Recent Posts

  • Biovista Harnesses New Kinds of Augmented and Artificial Intelligence to Address COVID-19 August 25, 2020
  • Repositioning Safety May 22, 2020
  • Artificial Intelligence firm Biovista repositions four promising therapeutics against COVID-19 April 22, 2020
  • Business Development Agent in Japan February 12, 2020
  • High Throughput Layout and Copy Paste July 5, 2019

Biovista Vizit

Biovista Vizit

  • Try it!
  • Blog
  • Vizit Graphs

COMPLEMENT PATHWAY

Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome

June 19, 2020COVID-19, Vizit Graphs
Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome

Eculizumab is a biologic therapy, a complement C5 inhibitor, and has recently shown promise in COVID-19. The graph provides an important step towards elucidating the MoA of this drug in COVID-19. Explore the live graph.

Vizit Graphs Tag Cloud

ALZHEIMER'S DISEASE RAS AGING CELL PROLIFERATION PSEUDOMONAS AERUGINOSA INFLAMMATION TMPRSS2 COVID-19 IMMUNITY NFKB1 SARS-COV-2 IMMUNE RESPONSE ESCHERICHIA COLI MYALGIA INSULIN HELICOBACTER PYLORI IL6 ACE2 METFORMIN CD4 COGNITION COAGULATION CANCER PARKINSON DISEASE STAPHYLOCOCCUS AUREUS IFNG AUTOPHAGY ANGIOTENSIN II CANDIDA ALBICANS IL1B ALBUMIN APOPTOTIC PROCESS CASP3 NEUTROPHILS ACE IL2 PD-1 LISTERIA MONOCYTOGENES TNF LACTATE DEHYDROGENASE IL10 CELL DIFFERENTIATION INFLAMMATORY RESPONSE RHEUMATOID ARTHRITIS INTERFERON

© 2021 Biovista Vizit All Rights Reserved.